1
|
George AA, John SJ, Lucero LM, Eaton JB, Jaiswal E, Christensen SB, Gajewiak J, Watkins M, Cao Y, Olivera BM, Im W, McIntosh JM, Whiteaker P. Analogs of α-conotoxin PnIC selectively inhibit α7β2- over α7-only subtype nicotinic acetylcholine receptors via a novel allosteric mechanism. FASEB J 2024; 38:e23374. [PMID: 38161283 PMCID: PMC10782225 DOI: 10.1096/fj.202302079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 12/01/2023] [Indexed: 01/03/2024]
Abstract
This study was undertaken to identify and characterize the first ligands capable of selectively identifying nicotinic acetylcholine receptors containing α7 and β2 subunits (α7β2-nAChR subtype). Basal forebrain cholinergic neurons express α7β2-nAChR. Here, they appear to mediate neuronal dysfunction induced by the elevated levels of oligomeric amyloid-β associated with early Alzheimer's disease. Additional work indicates that α7β2-nAChR are expressed across several further critically important cholinergic and GABAergic neuronal circuits within the central nervous system. Further studies, however, are significantly hindered by the inability of currently available ligands to distinguish heteromeric α7β2-nAChR from the closely related and more widespread homomeric α7-only-nAChR subtype. Functional screening using two-electrode voltage-clamp electrophysiology identified a family of α7β2-nAChR-selective analogs of α-conotoxin PnIC (α-CtxPnIC). A combined electrophysiology, functional kinetics, site-directed mutagenesis, and molecular dynamics approach was used to further characterize the α7β2-nAChR selectivity and site of action of these α-CtxPnIC analogs. We determined that α7β2-nAChR selectivity of α-CtxPnIC analogs arises from interactions at a site distinct from the orthosteric agonist-binding site shared between α7β2- and α7-only-nAChR. As numerous previously identified α-Ctx ligands are competitive antagonists of orthosteric agonist-binding sites, this study profoundly expands the scope of use of α-Ctx ligands (which have already provided important nAChR research and translational breakthroughs). More immediately, analogs of α-CtxPnIC promise to enable, for the first time, both comprehensive mapping of the distribution of α7β2-nAChR and detailed investigations of their physiological roles.
Collapse
Affiliation(s)
- Andrew A. George
- Department of Pharmacology and Toxicology, School of MedicineVirginia Commonwealth UniversityRichmondVirginiaUSA
| | - Sabin J. John
- Department of Pharmacology and Toxicology, School of MedicineVirginia Commonwealth UniversityRichmondVirginiaUSA
- Department of Life SciencesUniversity of BathBathUK
| | - Linda M. Lucero
- Department of NeurobiologyBarrow Neurological InstitutePhoenixArizonaUSA
| | - J. Brek Eaton
- Department of NeurobiologyBarrow Neurological InstitutePhoenixArizonaUSA
| | - Ekta Jaiswal
- Department of NeurobiologyBarrow Neurological InstitutePhoenixArizonaUSA
| | | | - Joanna Gajewiak
- School of Biological SciencesUniversity of UtahSalt Lake CityUtahUSA
| | - Maren Watkins
- School of Biological SciencesUniversity of UtahSalt Lake CityUtahUSA
| | - Yiwei Cao
- Department of ChemistryLehigh UniversityBethlehemPennsylvaniaUSA
| | | | - Wonpil Im
- Department of ChemistryLehigh UniversityBethlehemPennsylvaniaUSA
| | - J. Michael McIntosh
- School of Biological SciencesUniversity of UtahSalt Lake CityUtahUSA
- George E. Wahlen Veterans Affairs Medical CenterSalt Lake CityUtahUSA
- Department of PsychiatryUniversity of UtahSalt Lake CityUtahUSA
| | - Paul Whiteaker
- Department of Pharmacology and Toxicology, School of MedicineVirginia Commonwealth UniversityRichmondVirginiaUSA
| |
Collapse
|
2
|
Wu Y, Zhang J, Ren J, Zhu X, Li R, Zhangsun D, Luo S. Substitution of D-Arginine at Position 11 of α-RgIA Potently Inhibits α7 Nicotinic Acetylcholine Receptor. Mar Drugs 2023; 21:326. [PMID: 37367650 DOI: 10.3390/md21060326] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 05/23/2023] [Accepted: 05/24/2023] [Indexed: 06/28/2023] Open
Abstract
Conotoxins are a class of disulfide-rich peptides found in the venom of cone snails, which have attracted considerable attention in recent years due to their potent activity on ion channels and potential for therapeutics. Among them, α-conotoxin RgIA, a 13-residue peptide, has shown great promise as a potent inhibitor of α9α10 nAChRs for pain management. In this study, we investigated the effect of substituting the naturally occurring L-type arginine at position 11 of the RgIA sequence with its D-type amino acid. Our results indicate that this substitution abrogated the ability of RgIA to block α9α10 nAChRs, but instead endowed the peptide with the ability to block α7 nAChR activity. Structural analyses revealed that this substitution induced significant alteration of the secondary structure of RgIA[11r], which consequently affected its activity. Our findings underscore the potential of D-type amino acid substitution as a promising strategy for designing novel conotoxin-based ligands targeting different types of nAChRs.
Collapse
Affiliation(s)
- Yong Wu
- School of Medicine, Guangxi University, Nanning 530004, China
| | - Junjie Zhang
- School of Medicine, Guangxi University, Nanning 530004, China
| | - Jie Ren
- School of Medicine, Guangxi University, Nanning 530004, China
| | - Xiaopeng Zhu
- School of Medicine, Guangxi University, Nanning 530004, China
| | - Rui Li
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Dongting Zhangsun
- School of Medicine, Guangxi University, Nanning 530004, China
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China
| | - Sulan Luo
- School of Medicine, Guangxi University, Nanning 530004, China
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China
| |
Collapse
|
3
|
Shelukhina I, Siniavin A, Kasheverov I, Ojomoko L, Tsetlin V, Utkin Y. α7- and α9-Containing Nicotinic Acetylcholine Receptors in the Functioning of Immune System and in Pain. Int J Mol Sci 2023; 24:ijms24076524. [PMID: 37047495 PMCID: PMC10095066 DOI: 10.3390/ijms24076524] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 03/26/2023] [Accepted: 03/28/2023] [Indexed: 04/03/2023] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) present as many different subtypes in the nervous and immune systems, muscles and on the cells of other organs. In the immune system, inflammation is regulated via the vagus nerve through the activation of the non-neuronal α7 nAChR subtype, affecting the production of cytokines. The analgesic properties of α7 nAChR-selective compounds are mostly based on the activation of the cholinergic anti-inflammatory pathway. The molecular mechanism of neuropathic pain relief mediated by the inhibition of α9-containing nAChRs is not fully understood yet, but the role of immune factors in this process is becoming evident. To obtain appropriate drugs, a search of selective agonists, antagonists and modulators of α7- and α9-containing nAChRs is underway. The naturally occurring three-finger snake α-neurotoxins and mammalian Ly6/uPAR proteins, as well as neurotoxic peptides α-conotoxins, are not only sophisticated tools in research on nAChRs but are also considered as potential medicines. In particular, the inhibition of the α9-containing nAChRs by α-conotoxins may be a pathway to alleviate neuropathic pain. nAChRs are involved in the inflammation processes during AIDS and other viral infections; thus they can also be means used in drug design. In this review, we discuss the role of α7- and α9-containing nAChRs in the immune processes and in pain.
Collapse
Affiliation(s)
| | | | | | | | | | - Yuri Utkin
- Correspondence: or ; Tel.: +7-495-3366522
| |
Collapse
|
4
|
A Novel α4/7-Conotoxin QuIA Selectively Inhibits α3β2 and α6/α3β4 Nicotinic Acetylcholine Receptor Subtypes with High Efficacy. Mar Drugs 2022; 20:md20020146. [PMID: 35200675 PMCID: PMC8878501 DOI: 10.3390/md20020146] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 02/07/2022] [Accepted: 02/14/2022] [Indexed: 12/10/2022] Open
Abstract
α6β4 nAChR is expressed in the peripheral and central nervous systems and is associated with pain, addiction, and movement disorders. Natural α-conotoxins (α-CTxs) can effectively block different nAChR subtypes with higher efficacy and selectivity. However, the research on α6β4 nAChR is relatively poor, partly because of the lack of available target-specific α-CTxs. In this study, we synthesized a novel α-4/7 conotoxin QuIA that was found from Conus quercinus. We investigated the efficacy of this peptide to different nAChR subtypes using a two-electrode voltage-clamp technique. Remarkably, we found α-QuIA inhibited the neuronal α3β2 and α6/α3β4 nAChR subtypes with significantly high affinity (IC50 was 55.7 nM and 90.68 nM, respectively), and did not block other nAChR subtypes even at a high concentration of 10 μM. In contrast, most α-CTxs have been determined so far to effectively block the α6/α3β4 nAChR subtype while also maintaining a similar higher efficacy against the closely related α6β2β3 and/or α3β4 subtypes, which are different from QuIA. In conclusion, α-QuIA is a novel α4/7-CTx, which has the potential to develop as an effective neuropharmacology tool to detect the function of α6β4 nAChR.
Collapse
|
5
|
Ho TNT, Abraham N, Lewis RJ. Unique Pharmacological Properties of α-Conotoxin OmIA at α7 nAChRs. Front Pharmacol 2021; 12:803397. [PMID: 34955864 PMCID: PMC8692984 DOI: 10.3389/fphar.2021.803397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 11/22/2021] [Indexed: 11/13/2022] Open
Abstract
OmIA, isolated from Conus omaria venom, is a potent antagonist at α7 nAChRs. We determined the co-crystal structure of OmIA with Lymnae stagnalis acetylcholine binding protein (Ls-AChBP) that identified His5, Val10 and Asn11 as key determinants for the high potency of OmIA at α7 nAChRs. Remarkably, despite a competitive binding mode observed in the co-crystal structure, OmIA and analogues displayed functional insurmountable antagonism at α7 and α3β4 nAChRs, except OmIA analogues having long side chain at position 10 ([V10Q]OmIA and [V10L]OmIA), which were partial insurmountable antagonist at α7 nAChRs in the presence of type II positive allosteric modulators (PAMs). A “two-state, two-step” model was used to explain these observations, with [V10Q]OmIA and [V10L]OmIA co-existing in a fast reversible/surmountable as well as a tight binding/insurmountable state. OmIA and analogues also showed biphasic-inhibition at α7 nAChRs in the presence of PNU120596, with a preference for the high-affinity binding site following prolonged exposure. The molecular basis of binding and complex pharmacological profile of OmIA at α7 nAChRs presented in here expands on the potential of α-conotoxins to probe the pharmacological properties of nAChRs and may help guide the development novel α7 modulators.
Collapse
Affiliation(s)
- Thao N T Ho
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia
| | - Nikita Abraham
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia
| | - Richard J Lewis
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia
| |
Collapse
|
6
|
Wang S, Zhu X, Zhangsun M, Wu Y, Yu J, Harvey PJ, Kaas Q, Zhangsun D, Craik DJ, Luo S. Engineered Conotoxin Differentially Blocks and Discriminates Rat and Human α7 Nicotinic Acetylcholine Receptors. J Med Chem 2021; 64:5620-5631. [PMID: 33902275 DOI: 10.1021/acs.jmedchem.0c02079] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The α7 nicotinic acetylcholine receptor (nAChR) is present in the central nervous system and plays an important role in cognitive function and memory. α-Conotoxin LvIB, identified from genomic DNA of Conus lividus, its three isomers and four globular isomer analogues were synthesized and screened at a wide range of nAChR subtypes. One of the analogues, amidated [Q1G,ΔR14]LvIB, was found to be a potent blocker of rat α7 nAChRs. Importantly, it differentiates between α7 nAChRs of human (IC50: 1570 nM) and rat (IC50: 97 nM). Substitutions between rat and human α7 nAChRs at three key mutation sites revealed that no single mutant could completely change the activity profile of amidated [Q1G,ΔR14]LvIB. Rather, we found that the combined influence of Gln141, Asn184, and Lys186 determines the α7 nAChR species specificity of this peptide. This engineered α4/4 conotoxin has potential applications as a template for designing ligands to selectively block human α7 nAChRs.
Collapse
Affiliation(s)
- Shuai Wang
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Key Laboratory for Marine Drugs of Haikou, School of Life and Pharmaceutical Sciences, Hainan University, Haikou 570228, China
| | - Xiaopeng Zhu
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Key Laboratory for Marine Drugs of Haikou, School of Life and Pharmaceutical Sciences, Hainan University, Haikou 570228, China.,Medical School, Guangxi University, Nanning 530004, China
| | - Manqi Zhangsun
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Key Laboratory for Marine Drugs of Haikou, School of Life and Pharmaceutical Sciences, Hainan University, Haikou 570228, China
| | - Yong Wu
- Medical School, Guangxi University, Nanning 530004, China
| | - Jinpeng Yu
- Medical School, Guangxi University, Nanning 530004, China
| | - Peta J Harvey
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Quentin Kaas
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Dongting Zhangsun
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Key Laboratory for Marine Drugs of Haikou, School of Life and Pharmaceutical Sciences, Hainan University, Haikou 570228, China.,Medical School, Guangxi University, Nanning 530004, China
| | - David J Craik
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Sulan Luo
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Key Laboratory for Marine Drugs of Haikou, School of Life and Pharmaceutical Sciences, Hainan University, Haikou 570228, China.,Medical School, Guangxi University, Nanning 530004, China
| |
Collapse
|
7
|
Mass spectrometric identification and denovo sequencing of novel conotoxins from vermivorous cone snail ( Conus inscriptus), and preliminary screening of its venom for biological activities in vitro and in vivo. Saudi J Biol Sci 2020; 28:1582-1595. [PMID: 33732044 PMCID: PMC7938137 DOI: 10.1016/j.sjbs.2020.12.032] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 12/15/2020] [Accepted: 12/17/2020] [Indexed: 12/12/2022] Open
Abstract
Venom of Conus inscriptus, a vermivorous cone snail found abundantly in the southern coastal waters was studied to yield conotoxins through proteomic analysis. A total of 37 conotoxins (4 with single disulfide bonds, 20 with two disulfide bonds and 11 three disulfide-bonded peptides) were identified using mass spectrometric analysis. Among them, amino acid sequences of 11 novel conopeptides with one, two and three disulfides belonging to different classes were derived through manual de novo sequencing. Based on the established primary sequence, they were pharmacologically classified into α conotoxins, µ conotoxins and contryphans. Except In1696 all other conopeptides have undergone C-terminal amidation. The natural venom exhibited 50% lethality at 304.82 µg/mL against zebrafish embryo and 130.31 µg/mL against brine shrimp nauplii. The anticonvulsant study of natural venom effectively reduced the locomotor activity against pentylenetetrazole (PTZ) treated zebrafish. This concludes that the venom peptides from Conus inscriptus exhibit potential anticonvulsant function, which leads to the discovery of lead molecules against seizures.
Collapse
|
8
|
Chandna R, Kaczanowska K, Taylor P, Kini RM. Drysdalin, a snake neurotoxin with higher affinity for soluble acetylcholine binding protein from Aplysia californica than from Lymnaea stagnalis. Toxicon 2020; 187:86-92. [PMID: 32889025 DOI: 10.1016/j.toxicon.2020.08.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 08/30/2020] [Accepted: 08/31/2020] [Indexed: 11/17/2022]
Abstract
Acetylcholine binding proteins (AChBPs), structural and functional surrogates of the extracellular binding domain of nicotinic acetylcholine receptor (nAChRs), in complex with various antagonists and agonists have provided detailed insights into the neurotransmitter binding site of nAChRs. The classical long-chain α-neurotoxins bungarotoxin (44-fold) and cobratoxin (7-fold) bind to Lymnaea stagnalis (Ls)-AChBP with higher affinity compared to Aplysia californica (Ac)-AChBP. In this study, we describe a novel long chain α-neurotoxin Drysdalin, which has higher binding affinity (7-fold) to Ac-AChBP when compared to Ls-AChBP. This suggests an involvement of different regions or modes of interaction of drysdalin, when compared to the bungarotoxin and cobratoxin. We also found that the C-terminal 24-amino acid residues of drysdalin are critical for the binding to Ac-AChBP and its removal caused ~90-fold reduction in affinity. Further to understand the interaction of drysdalin with Ac-AChBP, we studied the role of three non-conserved amino acid residues of drysdalin, namely Arg30, Leu34 and Ala37. Substitution of Arg30 with the conserved Phe residue caused a ~100-fold reduction, Leu34 with conserved Arg caused a ~6-fold reduction, whereas substitution of Ala37 with conserved Arg enhanced the binding by 3-fold. The dramatic influence of this carboxyl terminal sequence enriched in arginine and proline residues suggests that the toxin binding pose is influenced primarily by this extended sequence.
Collapse
Affiliation(s)
- Ritu Chandna
- Protein Science Laboratory, Department of Biological Sciences, National University of Singapore, 117543, Singapore
| | - Katarzyna Kaczanowska
- Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, 92093-0751, USA
| | - Palmer Taylor
- Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, 92093-0751, USA
| | - R Manjunatha Kini
- Protein Science Laboratory, Department of Biological Sciences, National University of Singapore, 117543, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117600, Singapore.
| |
Collapse
|
9
|
Interactions of the α3β2 Nicotinic Acetylcholine Receptor Interfaces with α-Conotoxin LsIA and its Carboxylated C-terminus Analogue: Molecular Dynamics Simulations. Mar Drugs 2020; 18:md18070349. [PMID: 32635340 PMCID: PMC7401271 DOI: 10.3390/md18070349] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 06/27/2020] [Accepted: 06/30/2020] [Indexed: 12/22/2022] Open
Abstract
Notably, α-conotoxins with carboxy-terminal (C-terminal) amidation are inhibitors of the pentameric nicotinic acetylcholine receptors (nAChRs), which are therapeutic targets for neurological diseases and disorders. The (α3)2(β2)3 nAChR subunit arrangement comprises a pair of α3(+)β2(−) and β2(+)α3(−) interfaces, and a β2(+)β2(−) interface. The β2(+)β2(−) interface has been suggested to have higher agonist affinity relative to the α3(+)β2(−) and β2(+)α3(−) interfaces. Nevertheless, the interactions formed by these subunit interfaces with α-conotoxins are not well understood. Therefore, in order to address this, we modelled the interactions between α-conotoxin LsIA and the α3β2 subtype. The results suggest that the C-terminal carboxylation of LsIA predominantly influenced the enhanced contacts of the conotoxin via residues P7, P14 and C17 on LsIA at the α3(+)β2(−) and β2(+)α3(−) interfaces. However, this enhancement is subtle at the β2(+)β2(−) site, which can compensate the augmented interactions by LsIA at α3(+)β2(−) and β2(+)α3(−) binding sites. Therefore, the divergent interactions at the individual binding interface may account for the minor changes in binding affinity to α3β2 subtype by C-terminal carboxylation of LsIA versus its wild type, as shown in previous experimental results. Overall, these findings may facilitate the development of new drug leads or subtype-selective probes.
Collapse
|
10
|
van Hout M, Valdes A, Christensen SB, Tran PT, Watkins M, Gajewiak J, Jensen AA, Olivera BM, McIntosh JM. α-Conotoxin VnIB from Conus ventricosus is a potent and selective antagonist of α6β4* nicotinic acetylcholine receptors. Neuropharmacology 2019; 157:107691. [PMID: 31255696 DOI: 10.1016/j.neuropharm.2019.107691] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Revised: 06/05/2019] [Accepted: 06/26/2019] [Indexed: 01/20/2023]
Abstract
α6-containing (α6*) nicotinic acetylcholine receptors (nAChRs) are expressed throughout the periphery and the central nervous system and constitute putative therapeutic targets in pain, addiction and movement disorders. The α6β2* nAChRs are relatively well studied, in part due to the availability of target specific α-conotoxins (α-Ctxs). In contrast, all native α-Ctxs identified that potently block α6β4 nAChRs exhibit higher potencies for the closely related α6β2β3 and/or α3β4 subtypes. In this study, we have identified a novel peptide from Conus ventricosus with pronounced selectivity for the α6β4 nAChR. The peptide-encoding gene was cloned from genomic DNA and the predicted mature peptide, α-Ctx VnIB, was synthesized. The functional properties of VnIB were characterized at rat and human nAChRs expressed in Xenopus oocytes by two-electrode voltage clamp electrophysiology. VnIB potently inhibited ACh-evoked currents at rα6β4 and rα6/α3β4 nAChRs, displayed ∼20-fold and ∼250-fold lower potencies at rα3β4 and rα6/α3β2β3 receptors, respectively, and exhibited negligible effects at eight other nAChR subtypes. Interestingly, even higher degrees of selectivity were observed for hα6/α3β4 over hα6/α3β2β3 and hα3β4 receptors. Finally, VnIB displayed fast binding kinetics at rα6/α3β4 (on-rate t½ = 0.87 min-1, off-rate t½ = 2.7 min-1). The overall preference of VnIB for β4* over β2* nAChRs is similar to the selectivity profiles of other 4/6 α-Ctxs. However, in contrast to previously identified native α-Ctxs targeting α6* nAChRs, VnIB displays pronounced selectivity for α6β4 nAChRs over both α3β4 and α6β2β3 receptors. VnIB thus represents a novel molecular probe for elucidating the physiological role and therapeutic properties of α6β4* nAChRs.
Collapse
Affiliation(s)
- Marloes van Hout
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| | - Amanda Valdes
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA
| | - Sean B Christensen
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA.
| | - Phuong T Tran
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA
| | - Maren Watkins
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA; Department of Pathology, University of Utah, Salt Lake City, UT, 84112, USA.
| | - Joanna Gajewiak
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA.
| | - Anders A Jensen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| | | | - J Michael McIntosh
- Department of Biology, University of Utah, Salt Lake City, UT, 84112, USA; Department of Psychiatry, University of Utah, Salt Lake City, UT, 84108, USA; George E. Wahlen Veterans Affair Medical Center, Salt Lake City, UT, 84148, USA.
| |
Collapse
|
11
|
Hone AJ, Fisher F, Christensen S, Gajewiak J, Larkin D, Whiteaker P, McIntosh JM. PeIA-5466: A Novel Peptide Antagonist Containing Non-natural Amino Acids That Selectively Targets α3β2 Nicotinic Acetylcholine Receptors. J Med Chem 2019; 62:6262-6275. [PMID: 31194549 DOI: 10.1021/acs.jmedchem.9b00566] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Pharmacologically distinguishing α3β2 nicotinic acetylcholine receptors (nAChRs) from closely related subtypes, particularly α6β2, has been challenging due to the lack of subtype-selective ligands. We created analogs of α-conotoxin (α-Ctx) PeIA to identify ligand-receptor interactions that could be exploited to selectively increase potency and selectivity for α3β2 nAChRs. A series of PeIA analogs were synthesized by replacing amino acid residues in the second disulfide loop with standard or nonstandard residues and assessing their activity on α3β2 and α6/α3β2β3 nAChRs heterologously expressed in Xenopus laevis oocytes. Asparagine11 was found to occupy a pivotal position, and when replaced with negatively charged amino acids, selectivity for α3β2 over α6/α3β2β3 nAChRs was substantially increased. Second generation peptides were then designed to further improve both potency and selectivity. One peptide, PeIA-5466, was ∼300-fold more potent on α3β2 than α6/α3β2β3 and is the most α3β2-selective antagonist heretofore reported.
Collapse
Affiliation(s)
| | | | | | | | | | | | - J Michael McIntosh
- George E. Whalen Veterans Affairs Medical Center , Salt Lake City , Utah 84148 , United States
| |
Collapse
|
12
|
Hone AJ, Talley TT, Bobango J, Huidobro Melo C, Hararah F, Gajewiak J, Christensen S, Harvey PJ, Craik DJ, McIntosh JM. Molecular determinants of α-conotoxin potency for inhibition of human and rat α6β4 nicotinic acetylcholine receptors. J Biol Chem 2018; 293:17838-17852. [PMID: 30249616 DOI: 10.1074/jbc.ra118.005649] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 09/20/2018] [Indexed: 12/15/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) containing α6 and β4 subunits are expressed by dorsal root ganglion neurons and have been implicated in neuropathic pain. Rodent models are often used to evaluate the efficacy of analgesic compounds, but species differences may affect the activity of some nAChR ligands. A previous candidate α-conotoxin-based therapeutic yielded promising results in rodent models, but failed in human clinical trials, emphasizing the importance of understanding species differences in ligand activity. Here, we show that human and rat α6/α3β4 nAChRs expressed in Xenopus laevis oocytes exhibit differential sensitivity to α-conotoxins. Sequence homology comparisons of human and rat α6β4 nAChR subunits indicated that α6 residues forming the ligand-binding pocket are highly conserved between the two species, but several residues of β4 differed, including a Leu-Gln difference at position 119. X-ray crystallography of α-conotoxin PeIA complexed with the Aplysia californica acetylcholine-binding protein (AChBP) revealed that binding of PeIA orients Pro13 in close proximity to residue 119 of the AChBP complementary subunit. Site-directed mutagenesis studies revealed that Leu119 of human β4 contributes to higher sensitivity of human α6/α3β4 nAChRs to α-conotoxins, and structure-activity studies indicated that PeIA Pro13 is critical for high potency. Human and rat α6/α3β4 nAChRs displayed differential sensitivities to perturbations of the interaction between PeIA Pro13 and residue 119 of the β4 subunit. These results highlight the potential significance of species differences in α6β4 nAChR pharmacology that should be taken into consideration when evaluating the activity of candidate human therapeutics in rodent models.
Collapse
Affiliation(s)
| | | | - Janet Bobango
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812
| | | | | | | | | | - Peta J Harvey
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | - David J Craik
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | - J Michael McIntosh
- From the Departments of Biology; Psychiatry, University of Utah, Salt Lake City, Utah 84112; George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah 84148.
| |
Collapse
|
13
|
Chen J, Liang L, Ning H, Cai F, Liu Z, Zhang L, Zhou L, Dai Q. Cloning, Synthesis and Functional Characterization of a Novel α-Conotoxin Lt1.3. Mar Drugs 2018; 16:md16040112. [PMID: 29614714 PMCID: PMC5923399 DOI: 10.3390/md16040112] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 03/16/2018] [Accepted: 03/22/2018] [Indexed: 01/28/2023] Open
Abstract
α-Conotoxins (α-CTxs) are small peptides composed of 11 to 20 amino acid residues with two disulfide bridges. Most of them potently and selectively target nicotinic acetylcholine receptor (nAChR) subtypes, and a few were found to inhibit the GABAB receptor (GABABR)-coupled N-type calcium channels (Cav2.2). However, in all of α-CTxs targeting both receptors, the disulfide connectivity arrangement "C¹-C³, C²-C⁴" is present. In this work, a novel α4/7-CTx named Lt1.3 (GCCSHPACSGNNPYFC-NH₂) was cloned from the venom ducts of Conus litteratus (C. litteratus) in the South China Sea. Lt1.3 was then chemically synthesized and two isomers with disulfide bridges "C¹-C³, C²-C⁴" and "C¹-C⁴, C²-C³" were found and functionally characterized. Electrophysiological experiments showed that Lt1.3 containing the common disulfide bridges "C¹-C³, C²-C⁴" potently and selectively inhibited α3β2 nAChRs and not GABABR-coupled Cav2.2. Surprisingly, but the isomer with the disulfide bridges "C¹-C⁴, C²-C³" showed exactly the opposite inhibitory activity, inhibiting only GABABR-coupled Cav2.2 and not α3β2 nAChRs. These findings expand the knowledge of the targets and selectivity of α-CTxs and provide a new structural motif to inhibit the GABABR-coupled Cav2.2.
Collapse
Affiliation(s)
- Jinqin Chen
- Beijing Institute of Biotechnology, Beijing 100071, China.
- Institute of Physical Science and Information Technology, Anhui University, Hefei 236041, China.
| | - Li Liang
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Huying Ning
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Fengtao Cai
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Zhuguo Liu
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Longxiao Zhang
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Liangyi Zhou
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Qiuyun Dai
- Beijing Institute of Biotechnology, Beijing 100071, China.
| |
Collapse
|
14
|
Discovery of peptide ligands through docking and virtual screening at nicotinic acetylcholine receptor homology models. Proc Natl Acad Sci U S A 2017; 114:E8100-E8109. [PMID: 28874590 DOI: 10.1073/pnas.1703952114] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Venom peptide toxins such as conotoxins play a critical role in the characterization of nicotinic acetylcholine receptor (nAChR) structure and function and have potential as nervous system therapeutics as well. However, the lack of solved structures of conotoxins bound to nAChRs and the large size of these peptides are barriers to their computational docking and design. We addressed these challenges in the context of the α4β2 nAChR, a widespread ligand-gated ion channel in the brain and a target for nicotine addiction therapy, and the 19-residue conotoxin α-GID that antagonizes it. We developed a docking algorithm, ToxDock, which used ensemble-docking and extensive conformational sampling to dock α-GID and its analogs to an α4β2 nAChR homology model. Experimental testing demonstrated that a virtual screen with ToxDock correctly identified three bioactive α-GID mutants (α-GID[A10V], α-GID[V13I], and α-GID[V13Y]) and one inactive variant (α-GID[A10Q]). Two mutants, α-GID[A10V] and α-GID[V13Y], had substantially reduced potency at the human α7 nAChR relative to α-GID, a desirable feature for α-GID analogs. The general usefulness of the docking algorithm was highlighted by redocking of peptide toxins to two ion channels and a binding protein in which the peptide toxins successfully reverted back to near-native crystallographic poses after being perturbed. Our results demonstrate that ToxDock can overcome two fundamental challenges of docking large toxin peptides to ion channel homology models, as exemplified by the α-GID:α4β2 nAChR complex, and is extendable to other toxin peptides and ion channels. ToxDock is freely available at rosie.rosettacommons.org/tox_dock.
Collapse
|
15
|
Dutertre S, Nicke A, Tsetlin VI. Nicotinic acetylcholine receptor inhibitors derived from snake and snail venoms. Neuropharmacology 2017. [PMID: 28623170 DOI: 10.1016/j.neuropharm.2017.06.011] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The nicotinic acetylcholine receptor (nAChR) represents the prototype of ligand-gated ion channels. It is vital for neuromuscular transmission and an important regulator of neurotransmission. A variety of toxic compounds derived from diverse species target this receptor and have been of elemental importance in basic and applied research. They enabled milestone discoveries in pharmacology and biochemistry ranging from the original formulation of the receptor concept, the first isolation and structural analysis of a receptor protein (the nAChR) to the identification, localization, and differentiation of its diverse subtypes and their validation as a target for therapeutic intervention. Among the venom-derived compounds, α-neurotoxins and α-conotoxins provide the largest families and still represent indispensable pharmacological tools. Application of modified α-neurotoxins provided substantial structural and functional details of the nAChR long before high resolution structures were available. α-bungarotoxin represents not only a standard pharmacological tool and label in nAChR research but also for unrelated proteins tagged with a minimal α-bungarotoxin binding motif. A major advantage of α-conotoxins is their smaller size, as well as superior selectivity for diverse nAChR subtypes that allows their development into ligands with optimized pharmacological and chemical properties and potentially novel drugs. In the following, these two groups of nAChR antagonists will be described focusing on their respective roles in the structural and functional characterization of nAChRs and their development into research tools. In addition, we provide a comparative overview of the diverse α-conotoxin selectivities that can serve as a practical guide for both structure activity studies and subtype classification. This article is part of the Special Issue entitled 'Venom-derived Peptides as Pharmacological Tools.'
Collapse
Affiliation(s)
- Sébastien Dutertre
- Institut des Biomolécules Max Mousseron, UMR 5247, Université Montpellier - CNRS, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France
| | - Annette Nicke
- Walther Straub Institute for Pharmacology and Toxicology, Ludwig-Maximilians-Universität, Nußbaumstr. 26, 80336 Munich, Germany.
| | - Victor I Tsetlin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya str.16/10, Moscow 117999, Russian Federation
| |
Collapse
|
16
|
Residues Responsible for the Selectivity of α-Conotoxins for Ac-AChBP or nAChRs. Mar Drugs 2016; 14:md14100173. [PMID: 27727162 PMCID: PMC5082321 DOI: 10.3390/md14100173] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 09/20/2016] [Accepted: 09/21/2016] [Indexed: 12/22/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) are targets for developing new drugs to treat severe pain, nicotine addiction, Alzheimer disease, epilepsy, etc. α-Conotoxins are biologically and chemically diverse. With 12–19 residues and two disulfides, they can be specifically selected for different nAChRs. Acetylcholine-binding proteins from Aplysia californica (Ac-AChBP) are homologous to the ligand-binding domains of nAChRs and pharmacologically similar. X-ray structures of the α-conotoxin in complex with Ac-AChBP in addition to computer modeling have helped to determine the binding site of the important residues of α-conotoxin and its affinity for nAChR subtypes. Here, we present the various α-conotoxin residues that are selective for Ac-AChBP or nAChRs by comparing the structures of α-conotoxins in complex with Ac-AChBP and by modeling α-conotoxins in complex with nAChRs. The knowledge of these binding sites will assist in the discovery and design of more potent and selective α-conotoxins as drug leads.
Collapse
|
17
|
Abraham N, Paul B, Ragnarsson L, Lewis RJ. Escherichia coli Protein Expression System for Acetylcholine Binding Proteins (AChBPs). PLoS One 2016; 11:e0157363. [PMID: 27304486 PMCID: PMC4909209 DOI: 10.1371/journal.pone.0157363] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 05/27/2016] [Indexed: 01/22/2023] Open
Abstract
Nicotinic acetylcholine receptors (nAChR) are ligand gated ion channels, identified as therapeutic targets for a range of human diseases. Drug design for nAChR related disorders is increasingly using structure-based approaches. Many of these structural insights for therapeutic lead development have been obtained from co-crystal structures of nAChR agonists and antagonists with the acetylcholine binding protein (AChBP). AChBP is a water soluble, structural and functional homolog of the extracellular, ligand-binding domain of nAChRs. Currently, AChBPs are recombinantly expressed in eukaryotic expression systems for structural and biophysical studies. Here, we report the establishment of an Escherichia coli (E. coli) expression system that significantly reduces the cost and time of production compared to the existing expression systems. E. coli can efficiently express unglycosylated AChBP for crystallography and makes the expression of isotopically labelled forms feasible for NMR. We used a pHUE vector containing an N-terminal His-tagged ubiquitin fusion protein to facilitate AChBP expression in the soluble fractions, and thus avoid the need to recover protein from inclusion bodies. The purified protein yield obtained from the E. coli expression system is comparable to that obtained from existing AChBP expression systems. E. coli expressed AChBP bound nAChR agonists and antagonists with affinities matching those previously reported. Thus, the E. coli expression system significantly simplifies the expression and purification of functional AChBP for structural and biophysical studies.
Collapse
Affiliation(s)
- Nikita Abraham
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Australia
| | - Blessy Paul
- Division of Molecular Cell Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Australia
| | - Lotten Ragnarsson
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Australia
| | - Richard J. Lewis
- Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Australia
| |
Collapse
|
18
|
Hone AJ, McIntosh JM, Azam L, Lindstrom J, Lucero L, Whiteaker P, Passas J, Blázquez J, Albillos A. α-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells. Mol Pharmacol 2015; 88:881-93. [PMID: 26330550 DOI: 10.1124/mol.115.100982] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 08/31/2015] [Indexed: 01/17/2023] Open
Abstract
Ligands that selectively inhibit human α3β2 and α6β2 nicotinic acetylcholine receptor (nAChRs) and not the closely related α3β4 and α6β4 subtypes are lacking. Current α-conotoxins (α-Ctxs) that discriminate among these nAChR subtypes in rat fail to discriminate among the human receptor homologs. In this study, we describe the development of α-Ctx LvIA(N9R,V10A) that is 3000-fold more potent on oocyte-expressed human α3β2 than α3β4 and 165-fold more potent on human α6/α3β2β3 than α6/α3β4 nAChRs. This analog was used in conjuction with three other α-Ctx analogs and patch-clamp electrophysiology to characterize the nAChR subtypes expressed by human adrenal chromaffin cells. LvIA(N9R,V10A) showed little effect on the acetylcholine-evoked currents in these cells at concentrations expected to inhibit nAChRs with β2 ligand-binding sites. In contrast, the β4-selective α-Ctx BuIA(T5A,P6O) inhibited >98% of the acetylcholine-evoked current, indicating that most of the heteromeric receptors contained β4 ligand-binding sites. Additional studies using the α6-selective α-Ctx PeIA(A7V,S9H,V10A,N11R,E14A) indicated that the predominant heteromeric nAChR expressed by human adrenal chromaffin cells is the α3β4* subtype (asterisk indicates the possible presence of additional subunits). This conclusion was supported by polymerase chain reaction experiments of human adrenal medulla gland and of cultured human adrenal chromaffin cells that demonstrated prominent expression of RNAs for α3, α5, α7, β2, and β4 subunits and a low abundance of RNAs for α2, α4, α6, and α10 subunits.
Collapse
Affiliation(s)
- Arik J Hone
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - J Michael McIntosh
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Layla Azam
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Jon Lindstrom
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Linda Lucero
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Paul Whiteaker
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Juan Passas
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Jesús Blázquez
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| | - Almudena Albillos
- Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
| |
Collapse
|
19
|
Wang S, Zhao C, Liu Z, Wang X, Liu N, Du W, Dai Q. Structural and Functional Characterization of a Novel α-Conotoxin Mr1.7 from Conus marmoreus Targeting Neuronal nAChR α3β2, α9α10 and α6/α3β2β3 Subtypes. Mar Drugs 2015; 13:3259-75. [PMID: 26023835 PMCID: PMC4483627 DOI: 10.3390/md13063259] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Accepted: 05/11/2015] [Indexed: 12/26/2022] Open
Abstract
In the present study, we synthesized and, structurally and functionally characterized a novel α4/7-conotoxin Mr1.7 (PECCTHPACHVSHPELC-NH2), which was previously identified by cDNA libraries from Conus marmoreus in our lab. The NMR solution structure showed that Mr1.7 contained a 310-helix from residues Pro7 to His10 and a type I β-turn from residues Pro14 to Cys17. Electrophysiological results showed that Mr1.7 selectively inhibited the α3β2, α9α10 and α6/α3β2β3 neuronal nicotinic acetylcholine receptors (nAChRs) with an IC50 of 53.1 nM, 185.7 nM and 284.2 nM, respectively, but showed no inhibitory activity on other nAChR subtypes. Further structure-activity studies of Mr1.7 demonstrated that the PE residues at the N-terminal sequence of Mr1.7 were important for modulating its selectivity, and the replacement of Glu2 by Ala resulted in a significant increase in potency and selectivity to the α3β2 nAChR. Furthermore, the substitution of Ser12 with Asn in the loop2 significantly increased the binding of Mr1.7 to α3β2, α3β4, α2β4 and α7 nAChR subtypes. Taken together, this work expanded our knowledge of selectivity and provided a new way to improve the potency and selectivity of inhibitors for nAChR subtypes.
Collapse
Affiliation(s)
- Shuo Wang
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Cong Zhao
- Department of Chemistry, Renmin University of China, Beijing 100872, China.
| | - Zhuguo Liu
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Xuesong Wang
- Department of Chemistry, Renmin University of China, Beijing 100872, China.
| | - Na Liu
- Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Weihong Du
- Department of Chemistry, Renmin University of China, Beijing 100872, China.
| | - Qiuyun Dai
- Beijing Institute of Biotechnology, Beijing 100071, China.
| |
Collapse
|
20
|
Kompella SN, Hung A, Clark RJ, Marí F, Adams DJ. Alanine scan of α-conotoxin RegIIA reveals a selective α3β4 nicotinic acetylcholine receptor antagonist. J Biol Chem 2014; 290:1039-48. [PMID: 25411242 DOI: 10.1074/jbc.m114.605592] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Activation of the α3β4 nicotinic acetylcholine receptor (nAChR) subtype has recently been implicated in the pathophysiology of various conditions, including development and progression of lung cancer and in nicotine addiction. As selective α3β4 nAChR antagonists, α-conotoxins are valuable tools to evaluate the functional roles of this receptor subtype. We previously reported the discovery of a new α4/7-conotoxin, RegIIA. RegIIA was isolated from Conus regius and inhibits acetylcholine (ACh)-evoked currents mediated by α3β4, α3β2, and α7 nAChR subtypes. The current study used alanine scanning mutagenesis to understand the selectivity profile of RegIIA at the α3β4 nAChR subtype. [N11A] and [N12A] RegIIA analogs exhibited 3-fold more selectivity for the α3β4 than the α3β2 nAChR subtype. We also report synthesis of [N11A,N12A]RegIIA, a selective α3β4 nAChR antagonist (IC50 of 370 nM) that could potentially be used in the treatment of lung cancer and nicotine addiction. Molecular dynamics simulations of RegIIA and [N11A,N12A]RegIIA bound to α3β4 and α3β2 suggest that destabilization of toxin contacts with residues at the principal and complementary faces of α3β2 (α3-Tyr(92), Ser(149), Tyr(189), Cys(192), and Tyr(196); β2-Trp(57), Arg(81), and Phe(119)) may form the molecular basis for the selectivity shift.
Collapse
Affiliation(s)
- Shiva N Kompella
- From the Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia
| | - Andrew Hung
- From the Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia
| | - Richard J Clark
- the School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia, and
| | - Frank Marí
- the Department of Chemistry & Biochemistry, Florida Atlantic University, Boca Raton, Florida 33431
| | - David J Adams
- From the Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia,
| |
Collapse
|
21
|
Isolation, purification and functional characterization of alpha-BnIA from Conus bandanus venom. Toxicon 2014; 91:155-63. [PMID: 25449095 DOI: 10.1016/j.toxicon.2014.10.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 09/30/2014] [Accepted: 10/07/2014] [Indexed: 11/23/2022]
Abstract
We report the isolation and characterization by proteomic approach of a native conopeptide, named BnIA, from the crude venom of Conus bandanus, a molluscivorous cone snail species, collected in the South central coast of Vietnam. Its primary sequence was determined by matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry using collision-induced dissociation and confirmed by Edman's degradation of the pure native fraction. BnIA was present in high amounts in the crude venom and the complete sequence of the 16 amino acid peptide was the following GCCSHPACSVNNPDIC*, with C-terminal amidation deduced from Edman's degradation and theoretical monoisotopic mass calculation. Sequence alignment revealed that its -C1C2X4C3X7C4- pattern belongs to the A-superfamily of conopeptides. The cysteine connectivity of BnIA was 1-3/2-4 as determined by partial-reduction technique, like other α4/7-conotoxins, reported previously on other Conus species. Additionally, we found that native α-BnIA shared the same sequence alignment as Mr1.1, from the closely related molluscivorous Conus marmoreus venom, in specimens collected in the same coastal region of Vietnam. Functional studies revealed that native α-BnIA inhibited acetylcholine-evoked currents reversibly in oocytes expressing the human α7 nicotinic acetylcholine receptors, and blocked nerve-evoked skeletal muscle contractions in isolated mouse neuromuscular preparations, but with ∼200-times less potency.
Collapse
|
22
|
Lebbe EKM, Peigneur S, Maiti M, Mille BG, Devi P, Ravichandran S, Lescrinier E, Waelkens E, D'Souza L, Herdewijn P, Tytgat J. Discovery of a new subclass of α-conotoxins in the venom of Conus australis. Toxicon 2014; 91:145-54. [PMID: 25194747 DOI: 10.1016/j.toxicon.2014.08.074] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 08/22/2014] [Accepted: 08/27/2014] [Indexed: 11/19/2022]
Abstract
Cone snails (Conus sp.) are poisonous animals that can be found in all oceans where they developed a venomous strategy to prey or to defend. The venom of these species contains an undeniable source of unique and potent pharmacologically active compounds. Their peptide compounds, called conotoxins, are not only interesting for the development of new pharmaceutical ligands, but they are also useful for studying their broad spectrum of targets. One conotoxin family in particular, the α-conotoxins, acts on nicotinic acetylcholine receptors (nAChRs) which dysfunctions play important roles in pathologies such as epilepsy, myasthenic syndromes, schizophrenia, Parkinson's disease and Alzheimer's disease. Here we define a new subclass of the α-conotoxin family. We purified the venom of a yet unexplored cone snail species, i.e. Conus australis, and we isolated a 16-amino acid peptide named α-conotoxin AusIA. The peptide has the typical α-conotoxin CC-Xm-C-Xn-C framework, but both loops (m/n) contain 5 amino acids, which has never been described before. Using conventional electrophysiology we investigated the response of synthetically made globular (I-III, II-IV) and ribbon (I-IV, II-III) AusIA to different nicotinic acetylcholine receptors. The α7 nAChR was the only receptor found to be blocked with a similar potency by both peptide-configurations. This suggests that both α5/5 conotoxin isomers might be present in the venom gland of C. australis. NMR spectroscopy showed that no secondary structures define the peptides' three-dimensional topology. Moreover, the ribbon configuration, which is generally considered to be non-native, is more stable than the globular isomer. Accordingly, our findings show relevancy concerning the α-conotoxin classification which might be helpful in the design of novel therapeutic compounds.
Collapse
Affiliation(s)
- Eline K M Lebbe
- Toxicology and Pharmacology, University of Leuven-KU Leuven, O&N2-P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium
| | - Steve Peigneur
- Toxicology and Pharmacology, University of Leuven-KU Leuven, O&N2-P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium
| | - Mohitosh Maiti
- Laboratory of Medicinal Chemistry, University of Leuven-KU Leuven, Rega Institute for Medical Research, Dept. of Pharmaceutical & Pharmacological Sciences, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Bea G Mille
- Toxicology and Pharmacology, University of Leuven-KU Leuven, O&N2-P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium
| | - Prabha Devi
- CSIR-National Institute of Oceanography, Dona Paula, 403 004 Goa, India
| | | | - Eveline Lescrinier
- Laboratory of Medicinal Chemistry, University of Leuven-KU Leuven, Rega Institute for Medical Research, Dept. of Pharmaceutical & Pharmacological Sciences, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Etienne Waelkens
- Laboratorium voor Proteïne Fosforylatie en Proteomics, University of Leuven-KU Leuven, O&N I-P.O. Box 901, Herestraat 49, 3000 Leuven, Belgium
| | - Lisette D'Souza
- CSIR-National Institute of Oceanography, Dona Paula, 403 004 Goa, India
| | - Piet Herdewijn
- Laboratory of Medicinal Chemistry, University of Leuven-KU Leuven, Rega Institute for Medical Research, Dept. of Pharmaceutical & Pharmacological Sciences, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Jan Tytgat
- Toxicology and Pharmacology, University of Leuven-KU Leuven, O&N2-P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium.
| |
Collapse
|
23
|
Structural basis for cooperative interactions of substituted 2-aminopyrimidines with the acetylcholine binding protein. Proc Natl Acad Sci U S A 2014; 111:10749-54. [PMID: 25006260 DOI: 10.1073/pnas.1410992111] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The nicotinic acetylcholine receptor (nAChR) and the acetylcholine binding protein (AChBP) are pentameric oligomers in which binding sites for nicotinic agonists and competitive antagonists are found at selected subunit interfaces. The nAChR spontaneously exists in multiple conformations associated with its activation and desensitization steps, and conformations are selectively stabilized by binding of agonists and antagonists. In the nAChR, agonist binding and the associated conformational changes accompanying activation and desensitization are cooperative. AChBP, which lacks the transmembrane spanning and cytoplasmic domains, serves as a homology model of the extracellular domain of the nAChRs. We identified unique cooperative binding behavior of a number of 4,6-disubstituted 2-aminopyrimidines to Lymnaea AChBP, with different molecular variants exhibiting positive, nH > 1.0, and negative cooperativity, nH < 1.0. Therefore, for a distinctive set of ligands, the extracellular domain of a nAChR surrogate suffices to accommodate cooperative interactions. X-ray crystal structures of AChBP complexes with examples of each allowed the identification of structural features in the ligands that confer differences in cooperative behavior. Both sets of molecules bind at the agonist-antagonist site, as expected from their competition with epibatidine. An analysis of AChBP quaternary structure shows that cooperative ligand binding is associated with a blooming or flare conformation, a structural change not observed with the classical, noncooperative, nicotinic ligands. Positively and negatively cooperative ligands exhibited unique features in the detailed binding determinants and poses of the complexes.
Collapse
|
24
|
Lebbe EKM, Peigneur S, Maiti M, Devi P, Ravichandran S, Lescrinier E, Ulens C, Waelkens E, D'Souza L, Herdewijn P, Tytgat J. Structure-function elucidation of a new α-conotoxin, Lo1a, from Conus longurionis. J Biol Chem 2014; 289:9573-83. [PMID: 24567324 DOI: 10.1074/jbc.m114.556175] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
α-Conotoxins are peptide toxins found in the venom of marine cone snails and potent antagonists of various subtypes of nicotinic acetylcholine receptors (nAChRs). nAChRs are cholinergic receptors forming ligand-gated ion channels in the plasma membranes of certain neurons and the neuromuscular junction. Because nAChRs have an important role in regulating transmitter release, cell excitability, and neuronal integration, nAChR dysfunctions have been implicated in a variety of severe pathologies such as epilepsy, myasthenic syndromes, schizophrenia, Parkinson disease, and Alzheimer disease. To expand the knowledge concerning cone snail toxins, we examined the venom of Conus longurionis. We isolated an 18-amino acid peptide named α-conotoxin Lo1a, which is active on nAChRs. To the best of our knowledge, this is the first characterization of a conotoxin from this species. The peptide was characterized by electrophysiological screening against several types of cloned nAChRs expressed in Xenopus laevis oocytes. The three-dimensional solution structure of the α-conotoxin Lo1a was determined by NMR spectroscopy. Lo1a, a member of the α4/7 family, blocks the response to acetylcholine in oocytes expressing α7 nAChRs with an IC50 of 3.24 ± 0.7 μM. Furthermore, Lo1a shows a high selectivity for neuronal versus muscle subtype nAChRs. Because Lo1a has an unusual C terminus, we designed two mutants, Lo1a-ΔD and Lo1a-RRR, to investigate the influence of the C-terminal residue. Lo1a-ΔD has a C-terminal Asp deletion, whereas in Lo1a-RRR, a triple-Arg tail replaces the Asp. They blocked the neuronal nAChR α7 with a lower IC50 value, but remarkably, both adopted affinity for the muscle subtype α1β1δε.
Collapse
Affiliation(s)
- Eline K M Lebbe
- From Toxicology and Pharmacology, University of Leuven (KU Leuven), Campus Gasthuisberg, O&N2, 3000 Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Sambasivarao SV, Roberts J, Bharadwaj VS, Slingsby JG, Rohleder C, Mallory C, Groome JR, McDougal OM, Maupin CM. Acetylcholine promotes binding of α-conotoxin MII at α3 β2 nicotinic acetylcholine receptors. Chembiochem 2014; 15:413-24. [PMID: 24420650 DOI: 10.1002/cbic.201300577] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Indexed: 11/09/2022]
Abstract
α-Conotoxin MII (α-CTxMII) is a 16-residue peptide with the sequence GCCSNPVCHLEHSNLC, containing Cys2-Cys8 and Cys3-Cys16 disulfide bonds. This peptide, isolated from the venom of the marine cone snail Conus magus, is a potent and selective antagonist of neuronal nicotinic acetylcholine receptors (nAChRs). To evaluate the impact of channel-ligand interactions on ligand-binding affinity, homology models of the heteropentameric α3β2-nAChR were constructed. The models were created in MODELLER with the aid of experimentally characterized structures of the Torpedo marmorata-nAChR (Tm-nAChR, PDB ID: 2BG9) and the Aplysia californica-acetylcholine binding protein (Ac-AChBP, PDB ID: 2BR8) as templates for the α3- and β2-subunit isoforms derived from rat neuronal nAChR primary amino acid sequences. Molecular docking calculations were performed with AutoDock to evaluate interactions of the heteropentameric nAChR homology models with the ligands acetylcholine (ACh) and α-CTxMII. The nAChR homology models described here bind ACh with binding energies commensurate with those of previously reported systems, and identify critical interactions that facilitate both ACh and α-CTxMII ligand binding. The docking calculations revealed an increased binding affinity of the α3β2-nAChR for α-CTxMII with ACh bound to the receptor, and this was confirmed through two-electrode voltage clamp experiments on oocytes from Xenopus laevis. These findings provide insights into the inhibition and mechanism of electrostatically driven antagonist properties of the α-CTxMIIs on nAChRs.
Collapse
Affiliation(s)
- Somisetti V Sambasivarao
- Chemical and Biological Engineering Department, Colorado School of Mines, 1500 Illinois Street, Golden, CO 80401 (USA)
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Luo S, Zhangsun D, Schroeder CI, Zhu X, Hu Y, Wu Y, Weltzin MM, Eberhard S, Kaas Q, Craik DJ, McIntosh JM, Whiteaker P. A novel α4/7-conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors. FASEB J 2014; 28:1842-53. [PMID: 24398291 DOI: 10.1096/fj.13-244103] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
This study was performed to discover and characterize the first potent α3β2-subtype-selective nicotinic acetylcholine receptor (nAChR) ligand. A novel α4/7-conotoxin, α-CTxLvIA, was cloned from Conus lividus. Its pharmacological profile at Xenopus laevis oocyte-expressed rat nAChR subtypes was determined by 2-electrode voltage-clamp electrophysiology, and its 3-dimensional (3D) structure was determined by NMR spectroscopy. α-CTx LvIA is a 16-aa C-terminally-amidated peptide with 2-disulfide bridges. Using rat subunits expressed in Xenopus oocytes, we found the highest affinity of α-CTxLvIA was for α3β2 nAChRs (IC50 8.7 nM), where blockade was reversible within 2 min. IC50 values were >100 nM at α6/α3β2β3, α6/α3β4, and α3β4 nAChRs, and ≥3 μM at all other subtypes tested. α3β2 vs. α6β2 subtype selectivity was confirmed for human-subunit nAChRs with much greater preference (300-fold) for α3β2 over α6β2 nAChRs. This is the first α-CTx reported to show high selectivity for human α3β2 vs. α6β2 nAChRs. α-CTxLvIA adopts two similarly populated conformations water: one (assumed to be bioactive) is highly structured, whereas the other is mostly random coil in nature. Selectivity differences with the similarly potent, but less selective, α3β2 nAChR antagonist α-CTx PeIA probably reside within the three residues, which differ in loop 2, given their otherwise similar 3D structures. α4/7-CTx LvIA is a new, potent, selective α3β2 nAChR antagonist, which will enable detailed studies of α3β2 nAChR structure, function, and physiological roles.
Collapse
Affiliation(s)
- Sulan Luo
- 1Key Laboratory of Tropical Biological Resources, Ministry of Education, Hainan University; Haikou, Hainan, 570228 China.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Isolation and characterization of α-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors. Biochem Pharmacol 2013; 86:791-9. [DOI: 10.1016/j.bcp.2013.07.016] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2013] [Revised: 07/16/2013] [Accepted: 07/16/2013] [Indexed: 11/19/2022]
|
28
|
Hone AJ, Ruiz M, Scadden M, Christensen S, Gajewiak J, Azam L, McIntosh JM. Positional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors. J Biol Chem 2013; 288:25428-25439. [PMID: 23846688 DOI: 10.1074/jbc.m113.482059] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The nicotinic acetylcholine receptor (nAChR) subtype α6β2* (the asterisk denotes the possible presence of additional subunits) has been identified as an important molecular target for the pharmacotherapy of Parkinson disease and nicotine dependence. The α6 subunit is closely related to the α3 subunit, and this presents a problem in designing ligands that discriminate between α6β2* and α3β2* nAChRs. We used positional scanning mutagenesis of α-conotoxin PeIA, which targets both α6β2* and α3β2*, in combination with mutagenesis of the α6 and α3 subunits, to gain molecular insights into the interaction of PeIA with heterologously expressed α6/α3β2β3 and α3β2 receptors. Mutagenesis of PeIA revealed that Asn(11) was located in an important position that interacts with the α6 and α3 subunits. Substitution of Asn(11) with a positively charged amino acid essentially abolished the activity of PeIA for α3β2 but not for α6/α3β2β3 receptors. These results were used to synthesize a PeIA analog that was >15,000-fold more potent on α6/α3β2β3 than α3β2 receptors. Analogs with an N11R substitution were then used to show a critical interaction between the 11th position of PeIA and Glu(152) of the α6 subunit and Lys(152) of the α3 subunit. The results of these studies provide molecular insights into designing ligands that selectively target α6β2* nAChRs.
Collapse
Affiliation(s)
| | | | | | | | | | | | - J Michael McIntosh
- the Departments of Biology and; From the Interdepartmental Program in Neuroscience and; Psychiatry, University of Utah, Salt Lake City, Utah 84132 and; the George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, Utah 84148.
| |
Collapse
|
29
|
Kim HW, McIntosh JM. α6 nAChR subunit residues that confer α-conotoxin BuIA selectivity. FASEB J 2012; 26:4102-10. [PMID: 22751014 DOI: 10.1096/fj.12-204487] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Nicotinic acetylcholine receptors (nAChRs) containing α6 and/or α4 subunits modulate the release of dopamine. However, few compounds can effectively discriminate between ligand-binding sites that contain α6 vs. α4 nAChR subunits. Using a chimeric (α6/α4) subunit, we showed that α-conotoxin BuIA binds the extracellular rat α6β2 vs. α4β2 interface with ∼60,000-fold selectivity. Chimeras containing residues from the α6 subunit were inserted into the homologous position of the α4 subunit to identify critical sequence segments. The region between residues 184 and 207 in the α6 subunit accounted for the potency difference. Chimeras within this region followed by point mutations were constructed for further definition. α6 Lys185, Thr187, and Ile188 form a triad of key residues that influence BuIA binding; when these 3 α6 residues were inserted into the α4 subunit, there was an ∼2000-fold increase in toxin potency. We used a crystal structure of BuIA bound to the acetylcholine-binding protein together with the structure of the Torepedo marmorata nAChR to build a homology model of BuIA bound to the interface between α6 and β2 subunits. The results indicate that the triad of α6 residues lies outside the C loop and is distantly located from bound BuIA (>10 Å). This suggests that alterations in potency are not caused by the direct interaction between the triad and BuIA. Instead, alterations in C-loop 3-dimensional structure and/or flexibility may account for differential potency. Thr198 and Tyr205 also contributed to BuIA potency. In addition, Thr198 caused BuIA potency differences between the closely related α6 and α3 subunits. Together, the findings provide insight into differences between the α6 and other α subunits that may be exploited by α-conotoxins to achieve binding selectivity.
Collapse
Affiliation(s)
- Hyun-Woo Kim
- Department of Marine Biology, Pukyong National University, Busan, South Korea.
| | | |
Collapse
|
30
|
Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus Venom Peptide Pharmacology. Pharmacol Rev 2012; 64:259-98. [DOI: 10.1124/pr.111.005322] [Citation(s) in RCA: 323] [Impact Index Per Article: 26.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
31
|
Franco A, Kompella SN, Akondi KB, Melaun C, Daly NL, Luetje CW, Alewood PF, Craik DJ, Adams DJ, Marí F. RegIIA: An α4/7-conotoxin from the venom of Conus regius that potently blocks α3β4 nAChRs. Biochem Pharmacol 2012; 83:419-26. [DOI: 10.1016/j.bcp.2011.11.006] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2011] [Revised: 11/04/2011] [Accepted: 11/07/2011] [Indexed: 11/26/2022]
|
32
|
Kasheverov IE, Zhmak MN, Khruschov AY, Tsetlin VI. Design of new α-conotoxins: from computer modeling to synthesis of potent cholinergic compounds. Mar Drugs 2011; 9:1698-1714. [PMID: 22072993 PMCID: PMC3210602 DOI: 10.3390/md9101698] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 08/29/2011] [Accepted: 09/16/2011] [Indexed: 11/16/2022] Open
Abstract
A series of 14 new analogs of α-conotoxin PnIA Conus pennaceus was synthesized and tested for binding to the human α7 nicotinic acetylcholine receptor (nAChR) and acetylcholine-binding proteins (AChBP) Lymnaea stagnalis and Aplysia californica. Based on computer modeling and the X-ray structure of the A. californica AChBP complex with the PnIA[A10L, D14K] analog, single and multiple amino acid substitutions were introduced in α-conotoxin PnIA aimed at compounds of higher affinity and selectivity. Three analogs, PnIA[L5H], PnIA[A10L, D14K] and PnIA[L5R, A10L, D14R], have high affinities for AChBPs or α7 nAChR, as found in competition with radioiodinated α-bungarotoxin. That is why we prepared radioiodinated derivatives of these α-conotoxins, demonstrated their specific binding and found that among the tested synthetic analogs, most had almost 10-fold higher affinity in competition with radioactive α-conotoxins as compared to competition with radioactive α-bungarotoxin. Thus, radioiodinated α-conotoxins are a more sensitive tool for checking the activity of novel α-conotoxins and other compounds quickly dissociating from the receptor complexes.
Collapse
Affiliation(s)
- Igor E. Kasheverov
- Author to whom correspondence should be addressed; E-Mail: or ; Tel.: +7-495-330-7374; Fax: +7-495-335-5733
| | | | | | | |
Collapse
|
33
|
Tomizawa M, Casida JE. Unique neonicotinoid binding conformations conferring selective receptor interactions. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2011; 59:2825-2828. [PMID: 21341671 DOI: 10.1021/jf1019455] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Neonicotinoid agonists selectively act on the insect nicotinic acetylcholine receptor (nAChR). The molecular basis for this specificity is deciphered by comparisons of two acetylcholine binding proteins (AChBPs) with distinct pharmacological profiles that serve as structural homologues for the nAChR subtypes. Aplysia AChBP has high neonicotinoid sensitivity, whereas Lymnaea AChBP has low neonicotinoid sensitivity, pharmacologies reminiscent of insect and vertebrate nAChR subtypes, respectively. The ligand-receptor interactions for these AChBPs were established by chemical and structural neurobiology approaches. Neonicotinoids and nicotinoids bind in a single conformation with Aplysia AChBP, wherein the electronegative nitro or cyano pharmacophore of the neonicotinoid faces in a reversed orientation relative to the cationic nicotinoid functionality. For Lymnaea AChBP, the neonicotinoids have two binding conformations in this vertebrate receptor model, which are completely inverted relative to each other, whereas nicotinoids are nestled in only one conserved conformation. Therefore, the unique binding conformations of nicotinic agonists determine the selective receptor interactions.
Collapse
Affiliation(s)
- Motohiro Tomizawa
- Faculty of Education, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
| | | |
Collapse
|
34
|
Nasiripourdori A, Taly V, Grutter T, Taly A. From toxins targeting ligand gated ion channels to therapeutic molecules. Toxins (Basel) 2011; 3:260-93. [PMID: 22069709 PMCID: PMC3202823 DOI: 10.3390/toxins3030260] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 02/01/2011] [Accepted: 03/16/2011] [Indexed: 11/21/2022] Open
Abstract
Ligand-gated ion channels (LGIC) play a central role in inter-cellular communication. This key function has two consequences: (i) these receptor channels are major targets for drug discovery because of their potential involvement in numerous human brain diseases; (ii) they are often found to be the target of plant and animal toxins. Together this makes toxin/receptor interactions important to drug discovery projects. Therefore, toxins acting on LGIC are presented and their current/potential therapeutic uses highlighted.
Collapse
Affiliation(s)
| | - Valérie Taly
- Laboratory of Chemical Biology, Institut de Science et d'Ingénierie Supramoléculaires; ISIS/Université de Strasbourg, CNRS-UMR 7006, 8, allée Gaspard Monge, BP 70028, F-67083, Strasbourg Cedex, France;
| | - Thomas Grutter
- Laboratoire de Biophysicochimie des Récepteurs Canaux, UMR 7199 “Conception et Application de Molécules Bioactives” CNRS-Université de Strasbourg, 74 Route du Rhin-BP 60024, 67401 Illkirch Cedex, France;
| | - Antoine Taly
- Laboratoire de Biophysicochimie des Récepteurs Canaux, UMR 7199 “Conception et Application de Molécules Bioactives” CNRS-Université de Strasbourg, 74 Route du Rhin-BP 60024, 67401 Illkirch Cedex, France;
| |
Collapse
|
35
|
Peng C, Chen W, Sanders T, Chew G, Liu J, Hawrot E, Chi C. Chemical synthesis and characterization of two α4/7-conotoxins. Acta Biochim Biophys Sin (Shanghai) 2010; 42:745-53. [PMID: 20801929 DOI: 10.1093/abbs/gmq074] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
α-Conotoxins are small disulfide-constrained peptides that act as potent and selective antagonists on specific subtypes of nicotinic acetylcholine receptors (nAChRs). We previously cloned two α-conotoxins, Mr1.1 from the molluscivorous Conus marmoreus and Lp1.4 from the vermivorous Conus leopardus. Both of them have the typical 4/7-type framework of the subfamily of α-conotoxins that act on neuronal nAChRs. In this work, we chemically synthesized these two toxins and characterized their functional properties. The synthetic Mr1.1 could primarily inhibit acetylcholine (ACh)-evoked currents reversibly in the oocyte-expressed rat α7 nAChR, whereas Lp1.4 was an unexpected specific blocker of the mouse fetal muscle α1β1γδ receptor. Although their inhibition affinities were relatively low, their unique receptor recognition profiles make them valuable tools for toxin-receptor interaction studies. Mr1.1 could also suppress the inflammatory response to pain in vivo, suggesting that it should be further investigated with respect to its molecular role in analgesia and its mechanism or therapeutic target for the treatment of pain.
Collapse
Affiliation(s)
- Can Peng
- Institute of Protein Research, Tongji University, Shanghai, China
| | | | | | | | | | | | | |
Collapse
|
36
|
Armishaw CJ. Synthetic α-conotoxin mutants as probes for studying nicotinic acetylcholine receptors and in the development of novel drug leads. Toxins (Basel) 2010; 2:1471-99. [PMID: 22069647 PMCID: PMC3153239 DOI: 10.3390/toxins2061471] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2010] [Revised: 05/27/2010] [Accepted: 06/11/2010] [Indexed: 11/19/2022] Open
Abstract
α-Conotoxins are peptide neurotoxins isolated from venomous marine cone snails that are potent and selective antagonists for different subtypes of nicotinic acetylcholine receptors (nAChRs). As such, they are valuable probes for dissecting the role that nAChRs play in nervous system function. In recent years, extensive insight into the binding mechanisms of α-conotoxins with nAChRs at the molecular level has aided in the design of synthetic analogs with improved pharmacological properties. This review examines the structure-activity relationship studies involving α-conotoxins as research tools for studying nAChRs in the central and peripheral nervous systems and their use towards the development of novel therapeutics.
Collapse
Affiliation(s)
- Christopher J Armishaw
- Torrey Pines Institute for Molecular Studies, 11350 SW Village Pkwy, Port St Lucie, FL 34987, USA.
| |
Collapse
|
37
|
Abstract
Venoms of snakes, scorpions, spiders, insects, sea anemones, and cone snails are complex mixtures of mostly peptides and small proteins that have evolved for prey capture and/or defense. These deadly animals have long fascinated scientists and the public. Early studies isolated lethal components in the search for cures and understanding of their mechanisms of action. Ion channels have emerged as targets for many venom peptides, providing researchers highly selective and potent molecular probes that have proved invaluable in unraveling ion channel structure and function. This minireview highlights molecular details of their toxin-receptor interactions and opportunities for development of peptide therapeutics.
Collapse
Affiliation(s)
- Sébastien Dutertre
- From Atheris Laboratories, CH-1233 Bernex-Geneva, Switzerland and
- the Institute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland 4067, Australia
| | - Richard J. Lewis
- the Institute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland 4067, Australia
| |
Collapse
|
38
|
Bingham JP, Mitsunaga E, Bergeron ZL. Drugs from slugs--past, present and future perspectives of omega-conotoxin research. Chem Biol Interact 2010; 183:1-18. [PMID: 19800874 DOI: 10.1016/j.cbi.2009.09.021] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2009] [Revised: 09/03/2009] [Accepted: 09/24/2009] [Indexed: 12/18/2022]
Abstract
Peptides from the venom of carnivorous cone shells have provided six decades of intense research, which has led to the discovery and development of novel analgesic peptide therapeutics. Our understanding of this unique natural marine resource is however somewhat limited. Given the past pharmacological record, future investigations into the toxinology of these highly venomous tropical marine snails will undoubtedly yield other highly selective ion channel inhibitors and modulators. With over a thousand conotoxin-derived sequences identified to date, those identified as ion channel inhibitors represent only a small fraction of the total. Here we discuss our present understanding of conotoxins, focusing on the omega-conotoxin peptide family, and illustrate how such a seemingly simple snail has yielded a highly effective clinical drug.
Collapse
Affiliation(s)
- Jon-Paul Bingham
- Department of Molecular Biosciences and Bioengineering, University of Hawaii, Honolulu, HI 96822, USA.
| | | | | |
Collapse
|
39
|
Turner M, Eidemiller S, Martin B, Narver A, Marshall J, Zemp L, Cornell KA, McIntosh JM, McDougal OM. Structural basis for alpha-conotoxin potency and selectivity. Bioorg Med Chem 2009; 17:5894-9. [PMID: 19628399 DOI: 10.1016/j.bmc.2009.07.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2009] [Revised: 07/02/2009] [Accepted: 07/03/2009] [Indexed: 10/20/2022]
Abstract
Parkinson's disease is a debilitating movement disorder characterized by altered levels of alpha(6)beta(2) * ( * indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. alpha-Conotoxin MII (alpha-CTx MII) is a highly useful ligand to probe alpha(6)beta(2) nAChRs structure and function, but it does not discriminate among closely related alpha(6) * nAChR subtypes. Modification of the alpha-CTx MII primary sequence led to the identification of alpha-CTx MII[E11A], an analog with 500-5300-fold discrimination between alpha(6) * subtypes found in both human and non-human primates. alpha-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity alpha(6) nAChR, a subtype that is selectively lost in Parkinson's disease. Here, we present the three-dimensional solution structure for alpha-CTx MII[E11A] as determined by two-dimensional (1)H NMR spectroscopy to 0.13+/-0.09A backbone and 0.45+/-0.08A heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of alpha-CTx MII[E11A] relative to other members of the alpha-CTx family may be responsible for its exceptionally high affinity for alpha6alpha4beta2 * nAChR as well as discrimination between alpha(6)beta(2) and alpha(3)beta(2) containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for alpha(6) * nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson's disease.
Collapse
Affiliation(s)
- Matt Turner
- Department of Chemistry and Biochemistry, Boise State University, ID 83725-1520, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. Acta Pharmacol Sin 2009; 30:771-83. [PMID: 19448650 DOI: 10.1038/aps.2009.47] [Citation(s) in RCA: 137] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Cysteine-rich peptides from the venom of cone snails (Conus) target a wide variety of different ion channels. One family of conopeptides, the alpha-conotoxins, specifically target different isoforms of nicotinic acetylcholine receptors (nAChRs) found both in the neuromuscular junction and central nervous system. This family is further divided into subfamilies based on the number of amino acids between cysteine residues. The exquisite subtype selectivity of certain alpha-conotoxins has been key to the characterization of native nAChR isoforms involved in modulation of neurotransmitter release, the pathophysiology of Parkinson's disease and nociception. Structure/function characterization of alpha-conotoxins has led to the development of analogs with improved potency and/or subtype selectivity. Cyclization of the backbone structure and addition of lipophilic moieties has led to improved stability and bioavailability of alpha-conotoxins, thus paving the way for orally available therapeutics. The recent advances in phylogeny, exogenomics and molecular modeling promises the discovery of an even greater number of alpha-conotoxins and analogs with improved selectivity for specific subtypes of nAChRs.
Collapse
|
41
|
Tomizawa M, Casida JE. Molecular recognition of neonicotinoid insecticides: the determinants of life or death. Acc Chem Res 2009; 42:260-9. [PMID: 19053239 DOI: 10.1021/ar800131p] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Until the mid-20th century, pest insect control in agriculture relied on largely inorganic and botanical insecticides, which were inadequate. Then, the remarkable insecticidal properties of several organochlorines, organophosphates, methylcarbamates, and pyrethroids were discovered, leading to an arsenal of synthetic organics. The effectiveness of these insecticides, however, diminished over time due to the emergence of resistant insect strains with less sensitive molecular targets in their nervous systems. This created a critical need for a new type of neuroactive insecticide with a different yet highly sensitive target. Nicotine in tobacco extract was for centuries the best available agent to prevent sucking insects from damaging crops, although this alkaloid was hazardous to people and not very effective. The search for unusual structures and optimization revealed a new class of potent insecticides, known as neonicotinoids, which are similar to nicotine in their structure and action as agonists of the nicotinic acetylcholine receptor (nAChR). Fortunately, neonicotinoids are much more toxic to insects than mammals due in large part to differences in their binding site interactions at the corresponding nAChRs. This Account discusses the progress that has been made in defining the structural basis of neonicotinoid and nicotinoid potency and selectivity. The findings are based on comparisons of two acetylcholine binding proteins (AChBPs) with distinct pharmacological profiles that serve as structural surrogates for the extracellular ligand-binding domain of the nAChRs. Saltwater mollusk (Aplysia californica) AChBP has high neonicotinoid sensitivity, whereas freshwater snail (Lymnaea stagnalis) AChBP has low neonicotinoid and high nicotinoid sensitivities, pharmacologies reminiscent of insect and vertebrate nAChR subtypes, respectively. The ligand-receptor interactions for these AChBPs were established by photoaffinity labeling and X-ray crystallography. Both azidopyridinyl neonicotinoid and nicotinoid photoprobes bind in a single conformation with Aplysia AChBP; this is consistent with high-resolution crystal structures. Surprisingly, though, the electronegative nitro or cyano moiety of the neonicotinoid faced in a reversed orientation relative to the cationic nicotinoid functionality. For the Lymnaea AChBP, the azidoneonicotinoid probes modified two distinct and distant sites, while the azidonicotinoid probes, surprisingly, derivatized only one point. This meant that the neonicotinoids have two bound conformations in the vertebrate receptor model, which are completely inverted relative to each other, whereas nicotinoids appear buried in only one conserved conformation. Therefore, the unique binding conformations of nicotinic agonists in these insect and vertebrate receptor homologues define the basis for molecular recognition of neonicotinoid insecticides as the determinants of life or death.
Collapse
Affiliation(s)
- Motohiro Tomizawa
- Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy and Management, University of California, Berkeley, California 94720-3112
| | - John E. Casida
- Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy and Management, University of California, Berkeley, California 94720-3112
| |
Collapse
|
42
|
Babakhani A, Talley TT, Taylor P, McCammon JA. A virtual screening study of the acetylcholine binding protein using a relaxed-complex approach. Comput Biol Chem 2009; 33:160-70. [PMID: 19186108 DOI: 10.1016/j.compbiolchem.2008.12.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2008] [Accepted: 12/23/2008] [Indexed: 11/19/2022]
Abstract
The nicotinic acetylcholine receptor (nAChR) is a member of the ligand-gated ion channel family and is implicated in many neurological events. Yet, the receptor is difficult to target without high-resolution structures. In contrast, the structure of the acetylcholine binding protein (AChBP) has been solved to high resolution, and it serves as a surrogate structure of the extra-cellular domain in nAChR. Here we conduct a virtual screening study of the AChBP using the relaxed-complex method, which involves a combination of molecular dynamics simulations (to achieve receptor structures) and ligand docking. The library screened through comes from the National Cancer Institute, and its ligands show great potential for binding AChBP in various manners. These ligands mimic the known binders of AChBP; a significant subset docks well against all species of the protein and some distinguish between the various structures. These novel ligands could serve as potential pharmaceuticals in the AChBP/nAChR systems.
Collapse
Affiliation(s)
- Arneh Babakhani
- Department of Chemistry & Biochemistry, University of California at San Diego, 9500 Gilman Dr MC 0365, La Jolla, CA 92093-0365, USA
| | | | | | | |
Collapse
|
43
|
Peng C, Han Y, Sanders T, Chew G, Liu J, Hawrot E, Chi C, Wang C. alpha4/7-conotoxin Lp1.1 is a novel antagonist of neuronal nicotinic acetylcholine receptors. Peptides 2008; 29:1700-7. [PMID: 18588930 PMCID: PMC4826758 DOI: 10.1016/j.peptides.2008.05.028] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2008] [Revised: 05/26/2008] [Accepted: 05/27/2008] [Indexed: 11/18/2022]
Abstract
Cone snails comprise approximately 700 species of venomous molluscs which have evolved the ability to generate multiple toxins with varied and exquisite selectivity. alpha-Conotoxin is a powerful tool for defining the composition and function of nicotinic acetylcholine receptors which play a crucial role in excitatory neurotransmission and are important targets for drugs and insecticides. An alpha4/7 conotoxin, Lp1.1, originally identified by cDNA and genomic DNA cloning from Conus leopardus, was found devoid of the highly conserved Pro residue in the first intercysteine loop. To further study this toxin, alpha-Lp1.1 was chemically synthesized and refolded into its globular disulfide isomer. The synthetic Lp1.1 induced seizure and paralysis on freshwater goldfish and selectively reversibly inhibited ACh-evoked currents in Xenopus oocytes expressing rat alpha3beta2 and alpha6alpha3beta2 nAChRs. Comparing the distinct primary structure with other functionally related alpha-conotoxins could indicate structural features in Lp1.1 that may be associated with its unique receptor recognition profile.
Collapse
Affiliation(s)
- Can Peng
- Institute of Protein Research, Tongji University, Shanghai 200092, China
| | - Yuhong Han
- Institute of Protein Research, Tongji University, Shanghai 200092, China
| | - Tanya Sanders
- Department of Molecular Pharmacology, Physiology and Biotechnology, Brown Medical School, Providence, Rhode Island 02912, USA
| | - Geoffrey Chew
- Department of Molecular Pharmacology, Physiology and Biotechnology, Brown Medical School, Providence, Rhode Island 02912, USA
| | - Jing Liu
- Department of Molecular Pharmacology, Physiology and Biotechnology, Brown Medical School, Providence, Rhode Island 02912, USA
| | - Edward Hawrot
- Department of Molecular Pharmacology, Physiology and Biotechnology, Brown Medical School, Providence, Rhode Island 02912, USA
| | - Chengwu Chi
- Institute of Protein Research, Tongji University, Shanghai 200092, China
- Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
| | - Chunguang Wang
- Institute of Protein Research, Tongji University, Shanghai 200092, China
- Corresponding author and address: Chunguang Wang, Institute of Protein Research, Tongji University 1239 Siping Road, Shanghai 200092, China Tel.: +86-21-65984347 Fax: +86-21-65988403
| |
Collapse
|
44
|
Kamens HM, McKinnon CS, Li N, Helms ML, Belknap JK, Phillips TJ. The alpha 3 subunit gene of the nicotinic acetylcholine receptor is a candidate gene for ethanol stimulation. GENES BRAIN AND BEHAVIOR 2008; 8:600-9. [PMID: 18826434 DOI: 10.1111/j.1601-183x.2008.00444.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Alcohol and nicotine are coabused, and preclinical and clinical data suggest that common genes may influence responses to both drugs. A gene in a region of mouse chromosome 9 that includes a cluster of three nicotinic acetylcholine receptor (nAChR) subunit genes influences the locomotor stimulant response to ethanol. The current studies first used congenic mice to confirm the influential gene on chromosome 9. Congenic F(2) mice were then used to more finely map the location. Gene expression of the three subunit genes was quantified in strains of mice that differ in response to ethanol. Finally, the locomotor response to ethanol was examined in mice heterozygous for a null mutation of the alpha 3 nAChR subunit gene (Chrna3). Congenic data indicate that a gene on chromosome 9, within a 46 cM region that contains the cluster of nAChR subunit genes, accounts for 41% of the genetic variation in the stimulant response to ethanol. Greater expression of Chrna3 was found in whole brain and dissected brain regions relevant to locomotor behavior in mice that were less sensitive to ethanol-induced stimulation compared to mice that were robustly stimulated; the other two nAChR subunit genes in the gene cluster (alpha 5 and beta 4) were not differentially expressed. Locomotor stimulation was not expressed on the genetic background of Chrna3 heterozygous (+/-) and wild-type (+/+) mice; +/- mice were more sensitive than +/+ mice to the locomotor depressant effects of ethanol. Chrna3 is a candidate gene for the acute locomotor stimulant response to ethanol that deserves further examination.
Collapse
Affiliation(s)
- H M Kamens
- Department of Behavioral Neuroscience, Portland Alcohol Research Center, Oregon Health & Science University, VA Medical Center, Portland, OR 97239, USA
| | | | | | | | | | | |
Collapse
|
45
|
Atypical nicotinic agonist bound conformations conferring subtype selectivity. Proc Natl Acad Sci U S A 2008; 105:1728-32. [PMID: 18230720 DOI: 10.1073/pnas.0711724105] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The nicotinic acetylcholine (ACh) receptor (nAChR) plays a crucial role in excitatory neurotransmission and is an important target for drugs and insecticides. Diverse nAChR subtypes with various subunit combinations confer differential selectivity for nicotinic drugs. We investigated the subtype selectivity of nAChR agonists by comparing two ACh-binding proteins (AChBPs) as structural surrogates with distinct pharmacological profiles [i.e., Lymnaea stagnalis (Ls) AChBP of low neonicotinoid and high nicotinoid sensitivities and Aplysia californica (Ac) AChBP of high neonicotinoid sensitivity] mimicking vertebrate and insect nAChR subtypes, respectively. The structural basis of subtype selectivity was examined here by photoaffinity labeling. Two azidoneonicotinoid probes in the Ls-AChBP surprisingly modified two distinct and distant subunit interface sites: loop F Y164 of the complementary or (-)-face subunit and loop C Y192 of the principal or (+)-face subunit, whereas three azidonicotinoid probes derivatized only Y192. Both the neonicotinoid and nicotinoid probes labeled Ac-AChBP at only one position at the interface between loop C Y195 and loop E M116. These findings were used to establish structural models of the two AChBP subtypes. In the Ac-AChBP, the neonicotinoids and nicotinoids are nestled in similar bound conformations. Intriguingly, for the Ls-AChBP, the neonicotinoids have two bound conformations that are inverted relative to each other, whereas nicotinoids appear buried in only one conserved conformation as seen for the Ac-AChBP subtype. Accordingly, the subtype selectivity is based on two disparate bound conformations of nicotinic agonists, thereby establishing an atypical concept for neonicotinoid versus nicotinoid selectivity between insect and vertebrate nAChRs.
Collapse
|
46
|
Taylor P, Talley TT, Radic' Z, Hansen SB, Hibbs RE, Shi J. Structure-guided drug design: conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes. Biochem Pharmacol 2007; 74:1164-71. [PMID: 17826748 PMCID: PMC3341175 DOI: 10.1016/j.bcp.2007.07.038] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2007] [Revised: 07/21/2007] [Accepted: 07/23/2007] [Indexed: 10/23/2022]
Abstract
Neuronal nicotinic receptors, encoded by nine genes of the alpha and three of the beta type of subunits, and whose gene products assemble in distinct permutations as pentameric molecules, constitute a fertile area for structure-guided drug design. Design strategies are augmented by a wide variety of peptide, alkaloid and terpenoid toxins from various marine and terrestrial species that interact with nicotinic receptors. Also, acetylcholine-binding proteins from mollusks, as structural surrogates of the receptor that mimic its extracellular domain, provide atomic resolution templates for analysis of structure and response. Herein, we describe a structure-guided approach to nicotinic ligand design that employs crystallography of this protein as the basic template, but also takes into consideration the dynamic properties of the receptor molecules in their biological media. We present the crystallographic structures of several complexes of various agonists and antagonists that associate with the agonist site and can competitively block the action of acetylcholine. In so far as the extracellular domain is involved, we identify additional non-competitive sites at those subunit interfaces where agonists do not preferentially bind. Ligand association at these interface sites may modulate receptor function. Ligand binding is also shown by solution-based spectroscopic and spectrometric methods to affect the dynamics of discrete domains of the receptor molecule. The surrogate receptor molecules can then be employed to design ligands selective for receptor subtype through the novel methods of freeze-frame, click chemistry that uses the very structure of the target molecule as a template for synthesis of the inhibitor.
Collapse
Affiliation(s)
- Palmer Taylor
- Department of Pharmacology, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093-0657, USA.
| | | | | | | | | | | |
Collapse
|
47
|
Dutertre S, Ulens C, Büttner R, Fish A, van Elk R, Kendel Y, Hopping G, Alewood PF, Schroeder C, Nicke A, Smit AB, Sixma TK, Lewis RJ. AChBP-targeted alpha-conotoxin correlates distinct binding orientations with nAChR subtype selectivity. EMBO J 2007; 26:3858-67. [PMID: 17660751 PMCID: PMC1952216 DOI: 10.1038/sj.emboj.7601785] [Citation(s) in RCA: 133] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Accepted: 06/12/2007] [Indexed: 11/09/2022] Open
Abstract
Neuronal nAChRs are a diverse family of pentameric ion channels with wide distribution throughout cells of the nervous and immune systems. However, the role of specific subtypes in normal and pathological states remains poorly understood due to the lack of selective probes. Here, we used a binding assay based on acetylcholine-binding protein (AChBP), a homolog of the nicotinic acetylcholine ligand-binding domain, to discover a novel alpha-conotoxin (alpha-TxIA) in the venom of Conus textile. Alpha-TxIA bound with high affinity to AChBPs from different species and selectively targeted the alpha(3)beta(2) nAChR subtype. A co-crystal structure of Ac-AChBP with the enhanced potency analog TxIA(A10L), revealed a 20 degrees backbone tilt compared to other AChBP-conotoxin complexes. This reorientation was coordinated by a key salt bridge formed between Arg5 (TxIA) and Asp195 (Ac-AChBP). Mutagenesis studies, biochemical assays and electrophysiological recordings directly correlated the interactions observed in the co-crystal structure to binding affinity at AChBP and different nAChR subtypes. Together, these results establish a new pharmacophore for the design of novel subtype-selective ligands with therapeutic potential in nAChR-related diseases.
Collapse
Affiliation(s)
- Sébastien Dutertre
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - Chris Ulens
- Division of Molecular Carcinogenesis and Center for Biomedical Genetics, Netherlands Cancer Institute, Plesmanlaan, CX Amsterdam, The Netherlands
| | - Regina Büttner
- Department of Neurochemistry, Max Planck Institute for Brain Research, Deutschordenstrasse 46, Frankfurt am Main, Germany
| | - Alexander Fish
- Division of Molecular Carcinogenesis and Center for Biomedical Genetics, Netherlands Cancer Institute, Plesmanlaan, CX Amsterdam, The Netherlands
| | - René van Elk
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, Amsterdam, The Netherlands
| | - Yvonne Kendel
- Zentrum der Rechtsmedizin, University of Frankfurt, Frankfurt am Main, Germany
| | - Gene Hopping
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - Paul F Alewood
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - Christina Schroeder
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - Annette Nicke
- Department of Neurochemistry, Max Planck Institute for Brain Research, Deutschordenstrasse 46, Frankfurt am Main, Germany
| | - August B Smit
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, Amsterdam, The Netherlands
| | - Titia K Sixma
- Division of Molecular Carcinogenesis and Center for Biomedical Genetics, Netherlands Cancer Institute, Plesmanlaan, CX Amsterdam, The Netherlands
- Division of Molecular Carcinogenesis and Center for Biomedical Genetics, Netherlands Cancer Institute, Plesmanlaan, 1066 CX Amsterdam, The Netherlands. E-mail:
| | - Richard J Lewis
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
- Institute for Molecular Bioscience, The University of Queensland, Carmodty Rd, Brisbane, Queensland 4072, Australia. Tel.: +617 3346 2984; Fax: +617 3346 2101; E-mail:
| |
Collapse
|
48
|
Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. ChemMedChem 2007; 2:746-67. [PMID: 17295372 DOI: 10.1002/cmdc.200600207] [Citation(s) in RCA: 145] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The growing interest in nicotinic receptors, because of their wide expression in neuronal and non-neuronal tissues and their involvement in several important CNS pathologies, has stimulated the synthesis of a high number of ligands able to modulate their function. These membrane proteins appear to be highly heterogeneous, and still only incomplete information is available on their structure, subunit composition, and stoichiometry. This is due to the lack of selective ligands to study the role of nAChR under physiological or pathological conditions; so far, only compounds showing selectivity between alpha4beta2 and alpha7 receptors have been obtained. The nicotinic receptor ligands have been designed starting from lead compounds from natural sources such as nicotine, cytisine, or epibatidine, and, more recently, through the high-throughput screening of chemical libraries. This review focuses on the structure of the new agonists, antagonists, and allosteric ligands of nicotinic receptors, it highlights the current knowledge on the binding site models as a molecular modeling approach to design new compounds, and it discusses the nAChR modulators which have entered clinical trials.
Collapse
Affiliation(s)
- M Novella Romanelli
- Laboratory of Design, Synthesis, and Study of Biologically Active Heterocycles (HeteroBioLab), Department of Pharmaceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.
| | | | | | | | | | | |
Collapse
|